Quest Diagnostics Incorporated (NYSE: DGX) is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. The company reported 2008 revenue of $7.2 billion.

Quest Diagnostics offers diagnostic testing services through its network of principal laboratories in approximately 30 major metropolitan areas across the United States, with additional laboratories in India, Mexico and the United Kingdom. The company also operates four esoteric laboratories, 40 outpatient anatomic pathology laboratories, and 160 smaller, rapid-response laboratories. The company’s world-renowned Nichols Institute in San Juan Capistrano, California, and Chantilly, Virginia, specializes in esoteric testing, including gene-based testing, and conducts research and development.

Patients may have their specimens collected in any of the company’s approximately 2,000 conveniently located patient service centers. On a typical workday, the company processes more than 540,000 test orders. Quest Diagnostics laboratories operate 24 hours a day, 365 days a year, touching the lives of patients more than 150 million times each year.

Together with its MedPlus subsidiary, Quest Diagnostics also empowers healthcare organizations and clinicians with state-of-the-art connectivity solutions that improve patient care and practice management.

The company is also the leading provider of both pre-employment drugs-of-abuse screening for employers and risk assessment services for the life insurance industry. It is also the world’s second largest provider of clinical trials testing for new pharmaceuticals.

All data as of December 31, 2008.